Device is said to offer unrivalled speed, precision and accuracy for studying the CD spectra of proteins, chiral drugs and other optically active samples
Applied Photophysics (APL) introduces Chirascan, which it says is the world's most advanced circular dichroism (CD) spectrometer.
Development has taken three years to complete and resulted in this all-new, standard-setting CD spectrometer.
APL has been manufacturing kinetic spectrometers since 1971 and for the last decade has lead the market for specialised kinetic CD instruments.
Following extensive market research into the core requirements of the CD spectroscopist, four major themes appeared: the need for more light in the far-UV; sufficient functional sophistication to carry out challenging research yet simple enough to be used by a novice; the potential for high productivity; the availability of all this at an affordable price.
Chirascan's double-polarising prism optics facilitate exceptional light throughput, particularly in the far-UV, enabling the fast collection of high quality CD spectra. Intelligent acquisition software optimises measurements as they progress and ensures that results are meaningful.
A high-efficiency purging system and an automatic start-up procedure guarantee that Chirascan is fully operational with minimum delay.
Chirascan Windows software offers flexibility, ease of use and robust operation in a familiar environment. Experiments can be set up very quickly using drag and drop templates and client-server architecture provides the means to monitor experiments in progress remotely over a network.
All electronics modules incorporate self-test procedures that, together with calibration functions that are built into the software, ensure Chirascan is always working correctly. Continuous software monitoring verifies that Chirascan is operating optimally and warns of any condition that may compromise measurements.
A range of detection and application modules has been developed to complement the standard instrument, providing cost-effective and versatile upgrade paths.
Chirascan is said to be a flexible, future-proof investment that can adapt to evolving research needs.
